Sanofi (SNY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone, this is Thomas Gusslaten from the Zenufi IR team. Welcome to the Q2 2025 conference call for investors and analysts. As usual, you can find the slides on zenufi.com. Please turn to slide number 3. Here we have the usual forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements, which are subject to substantial risk and uncertainties that may cause active results of different material. We encourage you to read the disclaimer in our slide presentation. In addition, we refer you to our Form 20F on File with the US SEC and our French Universal Registration Document for a description of these risk factors. As usual, we will be making comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are in millions of euros and for Q2 2025, unless stated otherwise. Please turn to slide number four. First, we have a presentation, then we'll take your questions. We have kept the presentation as short as in the past, as other companies report today, and we aim at keeping the call to maximum one hour, all included. With Q&A, we have Brian, Olivier, Thomas to cover our global businesses, as well as Roy, our general counsel, and Brendan, head of manufacturing and supply. For the Q&A, you have two options in Zoom. Raise your hand or submit your question using the Q&A function. With this, I'll hand you over to Paul. Well, thank you and hello everyone on the call. We delivered another strong quarter with double digit sales growth. Our strategic focus on innovation continues to drive our top line performance with significant contributions from our new launches, vaccines and duplexes. The performance of our growth drivers made us more confident in our full year ...